Report Sections

See All Reports

  • HP:0002099: Asthma
  • Pneumonia (312) Abnormality of the cardiovascular system (29) Neoplasm (27) Respiratory tract infection (27) Hypoxemia (22) Depressivity (21) Diabetes mellitus (19) Acute kidney injury (19) Abnormal lung morphology (19) Thromboembolism (17) Hypertension (16) Anosmia (14) Myocardial infarction (14) Abnormality of coagulation (14) Stroke (13) Pulmonary embolism (13) Arthritis (12) Leukemia (12) Interstitial pneumonitis (12) Autistic behavior (11) Mental deterioration (11) Deep venous thrombosis (10) Type II diabetes mellitus (10) Pulmonary obstruction (10) Crohn's disease (10) Abnormality of the kidney (9) Autism (9) Obesity (9) Congestive heart failure (9) Chronic pulmonary obstruction (9) Chronic pain (9) Rheumatoid arthritis (8) Abnormality of the liver (8) Respiratory distress (8) Pulmonary fibrosis (8) Colitis (8) Myocarditis (8) Carcinoma (8) Ulcerative colitis (8) Behavioral abnormality (7) Dementia (7) Infertility (7) Inflammation of the large intestine (7) Pulmonary insufficiency (7) Low levels of vitamin D (7) Neoplasm of the lung (7) Type I diabetes mellitus (7) Psychosis (6) Coronary artery atherosclerosis (6) Lymphoma (6) Abnormality of the gastrointestinal tract (6) Chronic kidney disease (6) Sepsis (6) Renal insufficiency (5) Lymphopenia (5) Gastroparesis (5) Immunodeficiency (5) Systemic lupus erythematosus (5) Breast carcinoma (5) Peripheral arterial stenosis (5) Allergy (5) Encephalopathy (4) Hepatic fibrosis (4) Cardiac arrest (4) Dysphagia (4) Asthma (4) Alzheimer disease (4) Osteoarthritis (4) Neoplasm of the pancreas (4) Autoimmunity (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Sleep apnea (4) Prostate cancer (4) Neoplasm of head and neck (4) Addictive behavior (4) Insomnia (4) Obsessive-compulsive behavior (3) Seizure (3) Cardiomyopathy (3) Weight loss (3) Fever (3) Migraine (3) Pulmonary arterial hypertension (3) Bronchiectasis (3) Obstructive sleep apnea (3) Colon cancer (3) Reduced factor VIII activity (3) Malnutrition (3) Knee osteoarthritis (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Arrhythmia (3) Fatigue (3) Endometriosis (3) Non-small cell lung carcinoma (3) Neuroendocrine neoplasm (3) Hypercoagulability (3) Schizophrenia (3) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormal heart morphology (2) Tachycardia (2) Angina pectoris (2) Gastroesophageal reflux (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Mutism (2) Headache (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Atherosclerosis (2) Hypoventilation (2) Myelodysplasia (2) Psoriasiform dermatitis (2) Paroxysmal atrial fibrillation (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Cystoid macular edema (2) Hemeralopia (2) Cutaneous melanoma (2) Arteritis (2) Glioblastoma multiforme (2) Cervix cancer (2) Pulmonary edema (2) Ovarian neoplasm (2) Angioedema (2) Mania (2) Neoplasm of the large intestine (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Hypogeusia (1) Conductive hearing impairment (1) Abnormality of the eye (1) Cataract (1) Amblyopia (1) Periodontitis (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Abnormality of the skin (1) Jaundice (1) Lymphedema (1) Angiokeratoma corporis diffusum (1) Keratoconjunctivitis (1) Spasticity (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic steatosis (1) Hepatic failure (1) Hepatocellular carcinoma (1) Premature birth (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Pancreatitis (1) Abnormality of blood and blood-forming tissues (1) Gout (1) Diarrhea (1) Anorexia (1) Esophageal varix (1) Hypothermia (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Encephalitis (1) Waddling gait (1) Increased intracranial pressure (1) Celiac disease (1) Biliary cirrhosis (1) Hypotension (1) Osteomyelitis (1) Squamous cell carcinoma (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Back pain (1) Low back pain (1) Muscular dystrophy (1) Neonatal death (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Coronary artery stenosis (1) Chronic lymphatic leukemia (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Abnormal anterior horn cell morphology (1) Amyotrophic lateral sclerosis (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Inflammatory abnormality of the skin (1) Sinus tachycardia (1) Bronchiolitis (1) Postprandial hyperglycemia (1) Hepatitis (1) Erythroid hypoplasia (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Small cell lung carcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Subdural hemorrhage (1) Endocarditis (1) Toxemia of pregnancy (1) Myositis (1) Vaginal neoplasm (1) Cellulitis (1) Self-injurious behavior (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002099: Asthma

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (13)


    Name (Synonyms) Correlation
    drug323 Asthma controller therapies (incl. prednisone/prednisolone) Wiki 0.50
    drug1107 Dupilumab (SAR231893/REGN668) Wiki 0.50
    drug618 COVID 19 Convalescent Plasma Wiki 0.50
    Name (Synonyms) Correlation
    drug619 COVID 19 Diagnostic Test Wiki 0.50
    drug466 Best Standard of Care + CARDIO Wiki 0.50
    drug324 Asthma reliever therapies Wiki 0.50
    drug2090 Montelukast Oral Granules Wiki 0.50
    drug621 COVID 19 diagnostic test by PCR Wiki 0.50
    drug616 COVI-GUARD Wiki 0.50
    drug465 Best Standard of Care Wiki 0.50
    drug3433 Tezepelumab Wiki 0.35
    drug3221 Standard of Care Wiki 0.08
    drug2505 Placebo Wiki 0.05

    Correlated MeSH Terms (11)


    Name (Synonyms) Correlation
    D001249 Asthma NIH 1.00
    D001982 Bronchial Diseases NIH 0.50
    D006969 Hypersensitivity, Immediate NIH 0.50
    Name (Synonyms) Correlation
    D012130 Respiratory Hypersensitivity NIH 0.50
    D011657 Pulmonary Eosinophilia NIH 0.50
    D006967 Hypersensitivity, NIH 0.22
    D007154 Immune System Diseases NIH 0.20
    D008173 Lung Diseases, Obstructive NIH 0.14
    D008171 Lung Diseases, NIH 0.11
    D012140 Respiratory Tract Diseases NIH 0.11
    D007249 Inflammation NIH 0.09

    Correlated HPO Terms (3)


    Name (Synonyms) Correlation
    HP:0012393 Allergy HPO 0.22
    HP:0006536 Pulmonary obstruction HPO 0.16
    HP:0002088 Abnormal lung morphology HPO 0.11

    Clinical Trials

    Navigate: Correlations   HPO

    There are 4 clinical trials


    1 Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations

    Objective: To determine the extent to which high-dose (30mg) oral montelukast, added to standard treatment in children with moderate and severe acute exacerbations improves outcomes. Central Hypothesis: High-dose oral montelukast, added to standard treatment in children aged 5 to 17 years with moderate and severe acute asthma exacerbations, rapidly improves lung function, clinical severity, hospitalization rate and 72-hour symptom burden. Secondary Hypotheses: 1. There are greater effects of high-dose oral montelukast on lung function and on the secondary outcomes in the presence of respiratory viral detection or leukotriene-mediated inflammation; and 2. There is an interaction between viral detection and urinary leukotriene 4 level with treatment-response. Design: A two-arm, parallel randomized controlled trial of high-dose oral montelukast versus identical placebo, as add-on to standard treatment of systemic corticosteroid (SCS) and inhaled short-acting Beta-2-agonist (SABA), in children aged 5 to 17 years with moderate and severe acute asthma exacerbations. Intervention: High-dose oral montelukast added to standard treatment as one treatment-allocation arm, in comparison with standard treatment as the 2nd treatment-allocation arm. Primary and Important Secondary Endpoints: For the Primary Aim, the primary outcome measure to be compared between arms will be change of %-predicted airway resistance by impulse oscillometry (IOS) at 5Hz (%R5) at 2 hours after treatment initiation. Secondary outcomes will include improvement of %-predicted FEV1 (%FEV1), clinical severity measured using the validated Acute Asthma Intensity Research Score (AAIRS), hospitalization rate, and 72 hour symptom burden using the Pediatric Asthma Caregiver Diary (PACD). For the Secondary Aim, the investigators will determine (1) The effects of high-dose oral montelukast on lung function and on our secondary outcomes in the presence of nasal viruses and of greater leukotriene-mediated inflammation; and (2) The degree of interaction between viral detection and urinary leukotriene E4 (LTE4) level with treatment-response. Laboratory evaluations: The primary outcome (change of %R5) and select secondary outcomes (%FEV1, AAIRS, LTE4) will be measured before and again at 2 hours after treatment initiation. The other secondary outcomes will be measured at the time of hospitalization decision-making by the clinical team (hospitalization rate) or at 72-hours after treatment initiation (PACD).

    NCT03277170
    Conditions
    1. Asthma; Status
    2. Asthma in Children
    3. Asthma Acute
    4. Asthma Attack
    5. Acute Asthma Exacerbation
    Interventions
    1. Drug: Montelukast Oral Granules
    MeSH:Asthma
    HPO:Asthma

    Primary Outcomes

    Description: Change of percent-predicted airway resistance at 5Hz (%R5) by impulse oscillometrypost montelukast or control administration

    Measure: Change of percent-predicted airway resistance at 5Hz (%R5) by impulse oscillometry

    Time: Before and 2-hours after treatment with montelukast or placebo

    Secondary Outcomes

    Description: Change of percent-predicted forced expiratory volume in 1-second (FEV1)

    Measure: Change of percent-predicted forced expiratory volume in 1-second (FEV1)

    Time: Before and 2-hours after treatment with montelukast or placebo

    Description: Change of the Acute Asthma Intensity Research Score (AAIRS)

    Measure: Change of the Acute Asthma Intensity Research Score (AAIRS)

    Time: Before and 2-hours after treatment with montelukast or placebo

    Description: Leukotriene E4 (LTE4)

    Measure: Leukotriene E4 (LTE4)

    Time: Before treatment with montelukast or placebo

    Description: 72-hours symptom burden measured using the pediatric asthma caregiver diary (PACD)

    Measure: 72-hours symptom burden measured using the pediatric asthma caregiver diary (PACD)

    Time: Before and at 72-hours after treatment with montelukast or placebo

    Description: Hospitalization rate

    Measure: Hospitalization rate

    Time: 8-hours after treatment with montelukast or placebo
    2 One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study

    Primary Objective: To evaluate the long-term safety and tolerability of dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study. Secondary Objectives: - To evaluate the long-term efficacy of dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study. - To evaluate dupilumab in pediatric patients with asthma who participated in a previous dupilumab asthma clinical study with regard to: - Systemic exposure. - Anti-drug antibodies (ADAs). - Biomarkers.

    NCT03560466
    Conditions
    1. Asthma
    Interventions
    1. Drug: Dupilumab (SAR231893/REGN668)
    2. Drug: Asthma controller therapies (incl. prednisone/prednisolone)
    3. Drug: Asthma reliever therapies
    MeSH:Asthma
    HPO:Asthma

    Primary Outcomes

    Description: The number (n) and percentage (%) of patients experiencing any TEAE

    Measure: Treatment-emergent adverse events (TEAEs)

    Time: From Day 1 up to Week 64

    Secondary Outcomes

    Description: Annualized rate of severe asthma exacerbation events, during the treatment period

    Measure: Severe asthma exacerbation events

    Time: From Day 1 up to Week 52

    Description: Change in percentage (%) predicted forced expiratory volume in 1 second (FEV1) - Clinically significant changes from baseline

    Measure: Change in % predicted FEV1

    Time: From Day 1 up to Week 64

    Description: Change in absolute FEV1 - Clinically significant changes from baseline

    Measure: Change in absolute FEV1

    Time: From Day 1 up to Week 64

    Description: Change in forced vital capacity (FVC)

    Measure: Change in FVC

    Time: From Day 1 up to Week 64

    Description: Change in forced expiratory flow (FEF) 25-75%

    Measure: Change in FEF

    Time: From Day 1 up to Week 64

    Description: Serum dupilumab concentrations - Changes from first dupilumab injection

    Measure: Assessment of dupilumab concentration

    Time: From Day 1 up to Week 64

    Description: Titers of Anti-dupilumab antibodies

    Measure: Assessment of immunogenicity

    Time: From Day 1 up to Week 64

    Description: Blood: Eosinophil count

    Measure: Assessment of blood Eosinophil count

    Time: From Day 1 up to Week 64

    Description: Serum: total IgE

    Measure: Assessment of total immunoglobulin E (IgE)

    Time: From Day 1 up to Week 64
    3 A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults With Inadequately Controlled Asthma on Inhaled Corticosteroids and at Least One Additional Asthma Controller (CASCADE)

    A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma.

    NCT03688074
    Conditions
    1. Asthma
    2. Bronchial Diseases
    3. Respiratory Tract Diseases
    4. Lung Diseases, Obstructive
    5. Lung Diseases
    6. Respiratory Hypersensitivity
    7. Hypersensitivity, Immediate
    8. Hypersensitivity
    9. Immune System Diseases
    Interventions
    1. Biological: Tezepelumab
    2. Other: Placebo
    MeSH:Asthma Lung Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Bronchial Diseases Respiratory Hypersensitivity Hypersensitivity Immune System Diseases Hypersensitivity, Immediate Inflammation
    HPO:Abnormal lung morphology Allergy Asthma Pulmonary obstruction

    Primary Outcomes

    Description: The change from baseline in number of airway submucosal inflammatory cells/mm2 of bronchoscopic biopsies.

    Measure: The change from baseline in number of airway submucosal inflammatory cells/mm2 of bronchoscopic biopsies.

    Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.

    Secondary Outcomes

    Description: The change in reticular basement membrane (RBM) thickness from baseline, determined by microscopic evaluation of bronchoscopic biopsies

    Measure: The change in reticular basement membrane (RBM) thickness from baseline, determined by microscopic evaluation of bronchoscopic biopsies

    Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.

    Description: The change in % airway epithelial integrity from baseline determined by microscopic evaluation of bronchoscopic biopsies

    Measure: The change in % airway epithelial integrity from baseline determined by microscopic evaluation of bronchoscopic biopsies

    Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.

    Description: The change in number of airway submucosal inflammatory cells per mm2 from baseline, across the spectrum of T2 status, determined by microscopic evaluation of bronchoscopic biopsies

    Measure: The change in number of airway submucosal inflammatory cells per mm2 from baseline, across the spectrum of T2 status, determined by microscopic evaluation of bronchoscopic biopsies

    Time: Baseline, End of Treatment (EoT). The EoT will be performed at Week 28 for the majority of subjects but may be performed at later timepoints for some subjects (Week 32, etc.) due to up to 6 additional doses added during the Covid-19 pandemic.
    4 Randomized, Open-label, Parallel Study to Investigate Safety and Efficacy of CARDIO Softgels Plus Best Standard-of-care vs. Best Standard-of-care Alone on a Former Smoker and/or Steroid-resistant Asthma Population With COVID-19 Infection

    Corona virus disease 2019 (COVID-19) is caused by SARS-CoV-2, a plus-sense single-stranded RNA virus. After an incubation period, which typically lasts for 5-6 days, COVID-19 patients present with a mild illness that lasts for a few days. Common symptoms are reminiscent of the flu, and include fever, dry cough and dyspnea. A large percentage of patients resolve the infection whereas others progress onto adult respiratory distress syndrome (ARDS) which impedes gas exchange between the alveolar space and the bloodstream and creates the need for assisted respiration.The objectives of this randomized, open-label, parallel study is to investigate the safety and efficacy of CARDIO plus best standard-of-care in reducing the need for mechanical respiratory support, alleviating respiratory symptoms and reducing mortality in hospitalized former smoker and steroid-resistant asthma patients with COVID-19 infection.

    NCT04465513
    Conditions
    1. Asthma; Eosinophilic
    2. COVID
    3. Covid-19
    Interventions
    1. Dietary Supplement: Best Standard of Care + CARDIO
    2. Dietary Supplement: Best Standard of Care
    MeSH:Asthma Pulmonary Eosinophilia
    HPO:Asthma

    Primary Outcomes

    Description: Oxygen saturation rates (Best Standard of Care treatment (BSC) plus CARDIO vs. BSC alone)

    Measure: Oxygenation requirements during hospital stay (oxygen saturation rates)

    Time: On day of discharge if earlier than 28 days from baseline, then 28 days from baseline

    Description: Requirement for supplemental oxygen (Best Standard of Care treatment (BSC) plus CARDIO vs. BSC alone)

    Measure: Oxygenation requirements during hospital stay (supplemental Oxygen)

    Time: On day of discharge if earlier than 28 days from baseline, then 28 days from baseline

    Description: Requirement for advanced ventilator support (Best Standard of Care treatment (BSC) plus CARDIO vs. BSC alone)

    Measure: Oxygenation requirements during hospital stay (ventilator support)

    Time: On day of discharge if earlier than 28 days from baseline, then 28 days from baseline

    Secondary Outcomes

    Description: Assessed by the National Early Warning Score (NEWS) which is a standardized tool that assesses disease severity and monitoring of patients in hospital. An aggregate score of respiration rate, oxygen saturation, systolic blood pressure, pulse rate, level of consciousness and temperature and the score is increased if supplemental oxygen is required. Each parameter is based on a scale of 0 - 3. 0=good, 3=poor

    Measure: Clinical improvement

    Time: Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

    Description: Assessed by the WHO Ordinal Scale for Clinical Improvement which examines changes in clinical status and/or survival specific to COVID-19. This 8-point scale measures illness severity over time. 0 = no infection and 8 = dead

    Measure: Clinical status

    Time: Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

    Description: Serial chest CT or X-ray findings for the CARDIO softgel + BSC group will be compared with those of the BSC group.

    Measure: Serial chest CT or X-ray findings

    Time: Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

    Description: This is defined as sustained normalization of fever, respiratory rate, oxygen saturation, and alleviation of cough for at least 72 hours

    Measure: Time to clinical recovery

    Time: Day 28 from baseline or day of discharge

    Description: increase in SpO2/FiO2 of 50 mmHg or greater compared to the nadir SpO2/FiO2

    Measure: Time to improvement in oxygenation for at least 48 hours

    Time: Day 28 from baseline or day of discharge

    Description: The number of days from hospital admission to hospital discharge

    Measure: Hospitalization period

    Time: Day 28 from baseline or day of discharge

    Description: The total number of days on ventilator

    Measure: Amount of time on Ventilator

    Time: Day 28 from baseline or day of discharge

    Description: number of days in intensive care unit (ICU)

    Measure: Intensive Care stay

    Time: Day 28 from baseline or day of discharge

    Description: assessed by the COVID-19 QoL questionnaire which asks questions about incident of different parameters related to deteriorating. It is on a scale of 1-5. 1=completely disagree, 5 = completely agree

    Measure: Quality of life (QoL)

    Time: Day1, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

    Description: Death due to COVID-19 and other reasons

    Measure: All-cause mortality

    Time: Day 28 from baseline or day of discharge

    Description: Body temperatures

    Measure: Temperature measurements

    Time: Day 28 from baseline or day of discharge

    Description: measured using a pulse oximetry device, which is a non-invasive method to measure arterial oxygen saturation level.

    Measure: Oxygen saturation measurements

    Time: Day 28 from baseline or day of discharge

    Description: assessed by the COVID-19 QoL questionnaire which asks questions about incident of different parameters related to deteriorating. It is on a scale of 1-5. 1=completely disagree, 5 = completely agree

    Measure: COVID-19 QoL measurements

    Time: Day 28 from baseline or day of discharge

    Other Outcomes

    Description: Incidence of pre-emergent and post-emergent adverse events (AEs) and serious adverse events (SAEs)

    Measure: Adverse Events

    Time: During 15 days of supplementation or until day of discharge and during home follow up

    Description: systolic and diastolic

    Measure: Blood pressure

    Time: From baseline to 28 days thereafter

    Description: Heart rate values for the CARDIO softgel + BSC group will be compared with those of the BSC group using

    Measure: Heart rate

    Time: Everyday From baseline to 28 days thereafter

    Description: Frequency of clinically significant laboratory abnormalities.

    Measure: Abnormality in laboratory tests

    Time: Day 28 from baseline or day of discharge

    Description: BMI values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

    Measure: Body mass Index (BMI)

    Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

    Description: CBC values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

    Measure: Complete blood count (CBC)

    Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

    Description: AST values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

    Measure: Aspartate transaminase (AST)

    Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

    Description: ALT values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

    Measure: Alanine transaminase (ALT)

    Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

    Description: ALP values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

    Measure: Alkaline phosphatase (ALP)

    Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

    Description: Bilirubin values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

    Measure: Bilirubin

    Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

    Description: Sodium ion values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

    Measure: Sodium ion

    Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

    Description: Potassium ion values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

    Measure: Potassium ion

    Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

    Description: Chloride ion values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

    Measure: Chloride ion

    Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

    Description: Creatinine values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

    Measure: Creatinine

    Time: Daily From baseline to 28 days thereafter

    Description: eGFR values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

    Measure: eGFR

    Time: Daily From baseline to 28 days thereafter

    Description: HbA1c values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

    Measure: HbA1c

    Time: Daily From baseline to 28 days thereafter

    Description: eGFR values for the CARDIO softgel + BSC group will be compared with those of the BSC group using statistical analysis to determine significant difference between the two groups. Samples are taken in the days stated below.

    Measure: Glucose

    Time: Day 0, Day 10, Day 14, from baseline, Day 28 from baseline or day of discharge

    Description: CRP value only taken at baseline for every participant

    Measure: C-Reactive protein (CRP)

    Time: Baseline only

    HPO Nodes


    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook